**Definition:** Revlimid, a thalidomide analogue, is indicated in combination with dexamethasone for the treatment of patients with multiple myeloma who have received one prior therapy. Revlimid is also indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Revlimid is also indicated for the treatment of patients with mantle cell lymphoma whose disease has relapsed or progressed after two prior therapies, one of which included Velcade (bortezomib injection). Revlimid has a Boxed Warning regarding embryofetal toxicity, hematologic toxicity, and venous thromboembolism. Revlimid is only available through a restricted distribution program called the Revlimid Risk Evaluation Mitigation Strategy (REMS). Males and females must follow the required reproductive precautions.

**Please Note:** In order to be considered for coverage, this drug must be prescribed by or in consultation with a hematologist or oncologist.

**Medical Necessity:** Coverage of Revlimid is recommended in those who meet the following criteria:

1. **Mantle Cell Lymphoma.** Approve if the patient meets **ONE** of the following (a or b):
   
   a) The patient has tried two prior therapies or therapeutic regimens (e.g., Velcade; HyperCVAD [cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine] + Rituxan [rituximab injection]; the NORDIC regimen [dose-intensified induction immunochemotherapy with Rituxan + cyclophosphamide, vincristine, doxorubicin, prednisone alternating with Rituxan and high-dose cytarabine]; RCHOP/RICE [Rituxan, cyclophosphamide, doxorubicin, vincristine, prednisone]/[Rituxan, Ifex {ifosfamide injection}, carboplatin, etoposide]; Treanda (bendamustine injection) plus Rituxan; Velcade ± Rituxan; cladribine + Rituxan; FC (fludarabine, cyclophosphamide) ± Rituxan; PCR [pentostatin, cyclophosphamide, Rituxan]) and Imbruvica (ibrutinib capsules); OR
   
   b) The patient has tried one prior therapy or therapeutic regimen (examples listed above) and cannot take Velcade according to the prescribing physician.

2. **Multiple myeloma.** Approve.
3. **Myelodysplastic Syndrome (MDS).** Approve if the patient meets **ONE** of the following (a, b, or c):
   a) The patient has symptomatic anemia; OR
   b) The patient has transfusion-dependent anemia; OR
   c) The patient has anemia that is not controlled with an erythroid stimulating agent (ESA) e.g., Epogen/Procrit {epoetin alfa injection}, Aranesp {darbepoetin alfa injection}.

4. **Systemic Light Chain Amyloidosis.** Approve.

5. **Diffuse, Large B Cell Lymphoma (Non-Hodgkin’s Lymphoma).** Approve if the patient has tried one other medication treatment regimen (e.g., R-CHOP, dose-adjusted EPOCH [etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin] + Rituxan, RCEPP [Rituxan, cyclophosphamide, etoposide, prednisone, procarbazine], DHAP [dexamethasone, cisplatin, cytarabine] ± Rituxan, ICE [Ifex, carboplatin, etoposide] ± Rituxan, and Treanda ± Rituxan).

6. **Follicular Lymphoma (Non-Hodgkin’s Lymphoma).** Approve if the patient has tried one other medication treatment regimen (e.g., Treanda plus Rituxan, RCHOP, RCVP [Rituxan, cyclophosphamide, vincristine, prednisone] and Rituxan).

7. **Myelofibrosis.** Approve if the patient has tried one other therapy (e.g., Jakafi [ruxolitinib tablets], androgens [e.g., nandrolone, oxymetholone], Epogen, Procrit, Aranesp, prednisone, danazol, Thalomid [thalidomide capsules], melphalan, Myleran [busulfan tablets], alpha interferons, and hydroxyurea).

8. **Patients with another indication that is not listed but is cited in the National Comprehensive Cancer Network (NCCN) guidelines as a category 1, 2A, or 2B recommendation.** Prescriber will provide specific diagnosis for documentation. Approve.

9. **Patient has been started on Revlimid.** Approve for an indication or condition addressed as an approval in this document.